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Abstract: Withania somnifera is an important medicinal plant, which is used in traditional 
medicine to cure many diseases.  Flavonoids were determined in the extracts of W. 
somnifera  root (WSREt) and leaf (WSLEt). The amounts of total flavonoids found in 
WSREt and WSLEt were 530 and 520 mg/100 g dry weight (DW), respectively. 
Hypoglycaemic and hypolipidaemic effects of WSREt and WSLEt were also investigated 
in alloxan-induced diabetic rats. WSREt and WSLEt and the standard drug glibenclamide 
were orally administered daily to diabetic rats for eight weeks. After the treatment period, 
urine sugar, blood glucose, haemoglobin (Hb), glycosylated haemoglobin (HbA1C), liver 
glycogen, serum and tissues lipids, serum and tissues proteins, liver glucose-6-phosphatase 
(G6P) and serum enzymes like aspartate transaminase (AST), alanine transaminase (ALT), 
acid phosphatase (ACP) and alkaline phosphatase (ALP) levels were determined. The 
levels of urine sugar, blood glucose, HbA1C, G6P, AST, ALT, ACP, ALP, serum lipids 
except high density lipoprotein-bound cholesterol (HDL-c) and tissues like liver, kidney 
and heart lipids were significantly (p < 0.05) increased, however Hb, total protein, 
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albumin, albumin:globulin (A:G) ratio, tissues protein and glycogen were significantly   
(p < 0.05) decreased in alloxan-induced diabetic rats. Treatment of the diabetic rats with 
WSREt, WSLEt and glibenclamide restored the changes of the above parameters to their 
normal level after eight weeks of treatment, indicating that WSREt and WSLEt possess 
hypoglycaemic and hypolipidaemic activities in alloxan-induced diabetes mellitus (DM) rats. 
Keywords: alloxan; diabetic; Withania somnifera; hypoglycaemic; hypolipidaemic; 
flavonoids 
 
1. Introduction  
 
Plants have been the major source of drugs for the treatment of diabetes mellitus (DM) in Indian 
medicine and other ancient systems in the world, and for a long time DM has been treated orally with 
herbal medicines or their extracts [1], because plant products are frequently considered to be less toxic 
and more free from side effects than synthetic ones [2]. Furthermore, after the recommendations made 
by the WHO on DM, investigations on hypoglycaemic agents from medicinal plants have become 
more important and the search for more effective and safer hypoglycaemic agents has continued to be 
an important area of active research. World ethnobotanical information about medicinal plants reports 
that almost 800 plants could be used to control DM. Many herbs and plants have been described as 
possessing hypoglycaemic activity when taken orally [1,3]. Some of these plants have also been 
pharmacologically tested and shown to be of some value in human diabetes treatment.  
Withania somnifera (L.) Dunal, commonly known in Sanskrit as Ashwagandha, is a perennial plant 
belonging to the order Solanaceae. The pharmacological effects of the roots of W. somnifera are 
attributed to the presence of withanolides, a group of steroidal lactones [4]. Its leaves are used in 
Ayurvedic and Unani systems for treatment of tumors and tubercular glands [5]. A number of 
withanolide steroidal lactones have been isolated from the leaves of W. somnifera [6] and exhibit anti-
bacterial, anti-fungal and antitumor properties [7]. There are a number of reports elucidating the 
chemical and pharmacological properties of W. somnifera [8,9]. Hypoglycaemic activity of Trasina (an 
ayurvedic formulation) consisting of W. somnifera as one of the important constituents has been 
established beyond doubt and this activity may be due to its antioxidant properties [10]. It has been in 
used for a very long time for all age groups and for both sexes and even during pregnancy without any 
side effects. Tripathy et al. [11] have reviewed the traditional uses and antidiabetic activities of W. 
somnifera. Hypoglycaemic effects [12] and the effects of W. somnifera on insulin sensitivity in non- 
insulin dependent DM rats [13] have been reported. The chemistry and nutritional properties of 
phenolic compounds, including flavonoids, have been extensively reviewed [14]. Flavonoids are 
commonly found in all plants and also possess hypoglycemic and antidiabetic activities [15]. There is 
no report on flavonoid-containing extracts  of W. somnifera relating to antidiabetic and antihyper-
lipidaemic activities. Therefore, the present study was aimed at determining the hypoglycaemic   
and hypolipidaemic effects of W. somnifera root (WSREt) and leaf (WSLEt) extracts on alloxan-
induced DM.  Int. J. Mol. Sci. 2009, 10                 
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2. Results and Discussion 
 
2.1. Alloxan-induced DM 
 
Alloxan has been observed to cause a massive reduction of the β-cells of the islets of Langerhans 
and induce hyperglycaemic [16]. An observation in this study correlates with the previous research 
findings, in that the blood glucose level was significantly (p < 0.05) elevated in alloxan-induced 
diabetic rats [17].  
 
2.2. Mechanism of action of the standard drug glibenclamide 
 
Binding of glibenclamide with its receptor leads to the closure of the potassium channels which 
opens calcium channels for influx of Ca
2+ ions into the cytoplasm and release of insulin from the 
pancreatic islets. These K
+ channels are responsive to ATP/ADP ratio and close when the ratio 
increases because of an increase in glucose metabolism [18,19]. With chronic glibenclamide treatment, 
insulin production is not increased and may return to pretreatment values, but insulin efficacy 
continues and is thought to involve extrapancreatic mechanisms to increase insulin sensitivity in target 
tissues, such as liver and muscle as well as in other cells like monocytes and erythrocytes. This also 
leads to decrease hepatic glycogenolysis, gluconeogenesis and blood-glucose concentrations.  
 
2.3. Quantification of total flavonoids in WSREt and WSLEt  
 
Several researchers have reported that flavonoids have hypoglycaemic, hypolipidaemic and 
hypocholesterolaemic effects [20,21]. In the present study, the amount of total flavonoids was 
determined in WSREt and WSLEt using spectrophotometric analysis (Table 1). The amount of total 
flavonoids in quercetin equivalents (QE) was in 530 mg/100 g dry weight (DW) in WSREt and   
520 mg/100 g DW in WSLEt. From these results, it can be assumed that the flavonoids might be 
responsible for the hypoglycaemic and hypolipidaemic effects of W. somnifera root and leaf extracts.  
Table 1. Total content of flavonoids of Withania somnifera root and leaf extracts.  
Extracts 
Flavonoids  
(mg/100 g dry weight in 
quercetin equivalents) 
WSREt  530 ± 80 
WSLEt  520 ± 60 
Values are expressed as mean ± SD of three determinations. 
 
2.4. Effects of WSREt and WSLEt on body weight (bw) 
 
Changes in initial and final bw of normal control and experimental groups are shown in Table 2. 
Marked bw loss was observed in diabetic rats. The data obtained from this study showed that the 
treatment of WSREt, WSLEt and glibenclamide protects the diabetic rats from massive bw loss, when Int. J. Mol. Sci. 2009, 10                 
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given orally, daily for eight weeks. WSREt-, WSLEt- and glibenclamide-treated rats showed a 
recovery in final bw which was close to that of normal control rats. Moreover, the weight gain was 
lesser in the diabetic rats when compared to normal control rats. Thus, the bw loss due to catabolic 
effects seen in diabetic rats was only partially attenuated by the plant extracts.  
Table 2. Effects of W. somnifera (L.) extracts on body weight. 
Groups 
Initial weight 
(g) 
Final weight 
(g) 
Change in 
body weight (g) 
Change in 
body weight (%) 
Normal control  160.00 ± 8.91  205.17 ± 9.06  45.17 ± 6.78  + 28.23 
Diabetic control  172.00 ± 8.42  152.83 ± 8.78  19.17 ± 5.21  -11.15 
Diabetic + WSREt 
(100 mg/kg body weight) 
168.00 ± 9.24  208.00 ± 10.23  40.00 ± 7.64  + 23.81 
Diabetic + WSREt 
(200 mg/kg body weight) 
165.17 ± 10.19  207.33 ± 8.42  42.17 ± 6.42  + 25.53 
Diabetic + WSLEt 
(100 mg/kg body weight) 
165.00 ± 10.37  195.00 ± 7.32  30.00 ± 6.11  + 18.18 
Diabetic + WSLEt 
(200 mg/kg body weight) 
170.00 ± 8.16  212.67 ± 9.64  42.67 ± 7.56  + 25.10 
Diabetic + glibenclamide  170.00 ± 7.89  208.50 ± 8.16  38.50 ± 5.98  + 22.65 
Values are expressed as mean ± SD of six samples from each group. WSREt: W. somnifera root 
extract, WSLEt: W. somnifera leaf extract. 
 
2.5. Effects of WSREt and WSLEt on urine sugar, blood glucose, haemoglobin (Hb), glycosylated 
haemoglobin (HbA1C) and liver glycogen 
 
Induction of diabetes in the experimental rats was confirmed by the presence of a high blood 
glucose and low level of liver glycogen. The levels of urine sugar, blood glucose (308%), HbA1C 
(230%) were significantly (p < 0.05) increased, however Hb (66%) and liver glycogen (58%) were 
significantly (p < 0.05) decreased in alloxan induced diabetic rats when compared with those of 
normal control rats. Administration of WSREt and WSLEt at doses of 100 and 200 mg/kg bw to 
diabetic rats tends to bring the values to near normal. Among these two doses of WSREt and WSLEt, 
the dose of 200 mg/kg bw showed better results (Table 3). The levels of blood glucose (35%) and 
HbA1C (45%) were significantly (p < 0.05) decreased, however Hb (143%) and liver glycogen 
(150%) were significantly (p < 0.05) increased in diabetic rats treated with a dose of 200 mg/kg bw of 
WSREt when compared with those of diabetic rats. Therefore, the dose of 200 mg/kg bw of WSREt 
and WSLEt were selected for further analysis of lipid profile, protein profile, important serum and 
liver enzymes (Tables 4 – 8). 
It is not clear how WSREt and WSLEt cure diabetic rats under hyperglycaemic conditions. We 
assumed that WSREt and WSLEt may increase the pancreatic secretion of insulin from the cells of 
islets of Langerhan’s or both extracts may act like insulin substitutes. The effect of WSREt and 
WSLEt on the level of blood glucose in diabetic rats was more pronounced than that of glibenclamide. 
Moreover, the excess of glucose present in circulation during DM reacts with Hb to form HbA1C, a 
glycosylated Hb. HbA1C was found to increase in patients with DM and this increase is directly Int. J. Mol. Sci. 2009, 10                 
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proportional to the fasting blood glucose level [22]. These findings correlate with the present study, in 
which a significant change was observed in total Hb content. The HbA1C was also significantly   
(p < 0.05) increased in diabetic rats when compared to that of normal control rats, which indicates that 
the Hb gets glycosylated in the presence of hyperglycaemia. This is the first study in which a follow-
up was made on the changes in HbA1C concentration after the administration of WSREt and WSLEt 
alone. HbA1C has been found to be high over a long period of time in diabetes [23]. Therefore, the 
measurement of HbA1C is supposed to be a very vital index for glycaemic control. Glycogen synthesis 
in the rat liver and skeletal muscles was also impaired during diabetes [24]. Similar result was 
observed in this study. Diabetic rats treated with WSREt and WSLEt enhanced the rate of glycogenesis 
as indicated by higher amounts of hepatic glycogen.  
Table 3. Effects of W. somnifera (L.) extracts on urine sugar, blood glucose, haemoglobin, 
glycosylated haemoglobin and liver glycogen. 
Groups 
Urine 
Sugar 
Blood glucose 
(mg/dL) 
Hb 
(g/dL) 
HbA1C 
(mg/gHb) 
Liver 
glycogen 
(mg/g tissue) 
Normal control  -  92.17 ± 6.53 a  15.25 ± 1.35 c  1.84 ± 0.16 a  28.21 ± 2.27 d 
Diabetic control  +++  284.75 ± 15.86 d  10.20 ± 0.90 a  4.23 ±0.40 c  16.51 ± 1.46 a 
Diabetic + WSREt  
(100 mg/kg body weight) 
+  136.05 ± 4.92 c  12.92 ± 1.14 bc  2.05 ± 0.15 ab  22.39 ± 1.09 b 
Diabetic + WSREt  
(200 mg/kg body weight) 
+  100.12 ± 9.67 c  14.60 ± 1.29 de  1.90 ± 0.18 ab  24.78 ± 2.19 c 
Diabetic + WSLEt 
(100 mg/kg body weight) 
+  132.98 ± 6.52 c  12.28 ± 0.64 b  1.80 ± 0.09 a  25.45 ± 1.85 c 
Diabetic + WSLEt  
(200 mg/kg body weight) 
+  106.19 ± 4.71 b  14.82 ± 1.35 de  1.85 ± 0.18 a  28.14 ± 2.16 d 
Diabetic + glibenclamide  +  110.77 ± 2.75 b  13.76 ± 1.26 cd  2.15 ± 0.20 b  27.71 ± 1.45 d 
Values are expressed as mean ± SD of six samples from each group. Values with the same letter 
within columns are not significantly different using Duncan’s Multiple Range Test at 5% level  
(p ≤ 0.05). WSREt: W. somnifera root extract, WSLEt: W. somnifera leaf extract, haemoglobin 
(Hb), glycosylated haemoglobin (HbA1C).  
 
2.6. Effects of WSREt and WSLEt on serum and tissue lipids profile like total cholesterol (TC), 
triglycerides (TG) and phospholipids (PL) 
 
Effect of administering WSREt and WSLEt to diabetic rats on serum and tissues lipids like TC, TG, 
PL, serum high density lipoprotein-bound cholesterol (HDL-c), very low density lipoprotein-bound 
cholesterol (VLDL-c) and low-density lipoprotein-bound cholesterol (LDL-c) are presented in Tables 
4 – 6. The rise in blood sugar is accompanied by the increase in TC, TG, PL, LDL-c, VLDL-c and fall 
of HDL-c in diabetic rats. The levels of serum TC (201%), TG (147%), PL (161%), VLDL-c (147%) 
and LDL-c (195%) were significantly (p < 0.05) increased in diabetic rats when compared to those of 
normal control rats, while the level of serum HDL-c (70%) was significantly (p < 0.05) decreased in 
diabetic rats when compared to that of normal control rats (Table 4). The serum lipids like TC (54%), 
TG (75%), PL (65%), VLDL-c (75%) and LDL-c (64%) were significantly (p < 0.05) decreased and Int. J. Mol. Sci. 2009, 10                 
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HDL-c (132%) was significantly (p < 0.05) increased in diabetic rats treated with WSREt when 
compared to those of diabetic rats.  
The abnormal high concentration of serum lipids is mainly due to increase in the mobilization of 
free fatty acids from the peripheral fat deposits, because insulin inhibits the hormone sensitive lipase 
production. However, administering WSREt and WSLEt to diabetic rats tends to bring the values to 
near normal. Thus, WSREt and WSLEt treatments exhibited hypocholesterolaemic, hypotriglyceridaemic 
and hypophospholipidaemic effects while at the same time increasing the HDL-c.  
Table 4. Effects of W. somnifera (L.) extracts on serum lipid profile. 
Groups 
TC 
(mg/dL) 
TG 
(mg/dL) 
PL 
(mg/dL) 
HDL-c 
(mg/dL) 
VLDL-c 
(mg/dL) 
LDL–c 
(mg/dL) 
Normal control 
94.62 ± 
6.71 a 
78.14 ± 
6.92 a 
86.22 ± 
7.64 a 
24.08 ± 
1.82 c 
15.63 ± 
1.38 a 
38.43 ± 
7.04 a 
Diabetic control 
190.42 ± 
16.20 c 
114.82 ± 
10.17 c 
138.43 ± 
12.26 b 
16.82 ± 
1.59 a 
22.96 ± 
2.03 c 
75.03 ± 
4.55 c 
Diabetic + WSREt 
102.46 ± 
6.92 a 
86.43 ± 
7.65 ab 
89.89 ± 
7.96 a 
22.31 ± 
1.76 bc 
17.29 ± 
1.53 ab 
47.83 ± 
4.81 b 
Diabetic + WSLEt 
116.5 ± 
8.20 b 
90.86 ± 
8.05 b 
92.11 ± 
6.69 a 
20.46 ± 
1.68 b 
18.17 ± 
1.61 b 
52.23 ± 
8.72 b 
Diabetic + glibenclamide 
100.44 ± 
4.93 a 
88.44 ± 
6.42 b 
87.66 ± 
6.37 a 
22.35 ± 
1.84 bc 
17.69 ± 
1.28 b 
48.41 ± 
4.54 b 
Values are expressed as mean ± SD of six samples from each group.Values with the same letter 
within colums are not significantly different using Duncan’s Multiple Range Test (DMRT) at 5% 
level (p ≤ 0.05). Both WSREt and WSLEt were treated at 200 mg/kg bw. WSREt: W. somnifera 
root extract, WSLEt: W. somnifera leaf extract, TC: total cholesterol, TG: triglycerides, PL: 
phospholipids, HDL-c: high density lipoprotein-bound cholesterol, VLDL-c: very low density 
lipoprotein-bound cholesterol, LDL-c: low density lipoprotein-bound cholesterol.  
 
Furthermore, there were significant increases of TC (163% in liver, 160% in kidney and 212% in 
heart), TG (150% in liver, 187% in kidney and 255% in heart) and PL (186% in liver, 195% in kidney 
and 199% in heart) in alloxan induced diabetic rats when compared to those of normal control rats 
(Tables 5 and 6). On the other hand, TC (65% in liver, 68% in kidney and 52% in heart), TG (70% in 
liver, 58% in kidney and 45% in heart) and PL (55% in liver, 54% in kidney and 55% in heart) levels 
were significantly (p < 0.05) decreased in diabetic rats treated with WSREt when compared to those of 
diabetic rats. As a result, we found that the heart is the most targeted organ for the lipid accumulation 
in alloxan induced diabetic rats.  
Therefore, the elevated level of serum lipids in DM causes the risk of coronary heart disease [25]. It 
has been well established that DM alters the normal metabolism of tissues like liver, kidney and heart. 
Like diabetic rats treated with glibenclamide, the administration of WSREt and WSLEt to diabetic rats 
tends to bring the values to near normal. W. somnifera is known to have antioxidant properties [26] 
and this may reduce the susceptibility of lipids to oxidation and stabilize the membrane lipids thereby 
reducing oxidative stress.  
 Int. J. Mol. Sci. 2009, 10                 
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Table 5. Effects of W. somnifera (L.) extracts on liver and kidney lipids. 
Groups 
Liver Kidney 
TC  TG PL TC TG PL 
Normal control 
5.11 ± 
0.32 a 
7.27 ± 
0.68 a 
13.69 ± 
1.28 a 
6.22 ± 
0.43a 
4.88 ± 
0.28 a 
15.51 ± 
1.48 a 
Diabetic control 
8.33 ± 
0.86 d 
10.89 ± 
0.95 e 
25.51 ± 
1.86 d 
9.97 ± 
0.51e 
9.12 ± 
0.71 d 
30.21 ± 
2.53 e 
Diabetic + WSREt 
5.43 ± 
0.71 c 
7.69 ± 
0.59 b 
14.09 ± 
0.98 b 
6.82 ± 
0.62 c 
5.29 ± 
0.47 b 
16.29 ± 
1.21 c 
Diabetic + WSLEt 
6.52 ± 
0.65 cd 
8.43 ± 
0.48 d 
16.81 ± 
1.16 c 
7.69 ± 
0.53d 
6.86 ± 
0.36 c 
20.34 ± 
2.11 d 
Diabetic + glibenclamide 
5.29 ± 
0.47 b 
8.0 ± 
0.92 c 
14.21 ± 
1.54 b 
6.52 ± 
0.61b 
5.01 ± 
0.53 b 
16.05 ± 
1.82 b 
Values are expressed as mean ± SD of six samples from each group and represent mg/g wet tissue. 
Values with the same letter within colums are not significantly different using Duncan’s Multiple 
Range Test at 5% level (p ≤ 0.05). Both WSREt and WSLEt were treated at 200 mg/kg bw. 
WSREt: W. somnifera root extract, WSLEt: W. somnifera leaf extract, TC: total cholesterol, TG: 
triglycerides, PL: phospholipids. 
Table 6. Effects of W. somnifera (L.) extracts on heart lipids. 
Groups 
Heart 
TC TG  PL 
Normal control  3.13 ± 0.28 a  2.21 ± 0.21 a  8.16 ± 0.67 a 
Diabetic control  6.65 ± 0.75 e  5.63 ± 0.52 e  16.23 ± 1.25 e 
Diabetic + WSRET   3.49 ± 0.41 b  2.55 ± 0.26 bc  9.01 ± 0.61 c 
Diabetic + WSLET   4.82 ± 0.28 d  3.64 ± 0.24 d  11.46 ± 0.53 d 
Diabetic + glibenclamide  3.81 ± 0.31 c  2.43 ± 0.18 b  8.49 ± 0.49 b 
Values are expressed as mean ± SD of six samples from each group. Values with the same letter 
within columns are not significantly different using Duncan’s Multiple Range Test at 5% level  
(p  ≤ 0.05). Both WSREt and WSLEt were treated at 200 mg/kg body weight. WSREt: W. 
somnifera root extract, WSLEt: W. somnifera leaf extract, TC: total cholesterol, TG: triglycerides, 
PL: phospholipids. 
 
2.7. Effects of WSREt and WSLEt on serum and tissues protein  
 
The levels of total protein in serum (78%), liver (51%), kidney (70%) and heart (67%) and albumin 
(65%) and albumin:globulin (A:G) ratio (65%) in serum were significantly (p < 0.05) decreased in 
diabetic rats when compared to those of normal control rats. On the other hand, no change was 
observed in the level of serum globulin in diabetic rats when compared to that of normal control rats 
(Table 7). The total protein levels in serum (124%), liver (189%), kidney (141%) and heart (149%) 
and albumin (147%) and A:G ratio (161%) in serum were significantly (p < 0.05) increased in diabetic 
rats treated with WSREt when compared to those of diabetic rats. These results are accordance with 
the glibenclamide treated rats.  Int. J. Mol. Sci. 2009, 10                 
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Hypoalbuminemia was observed in DM, which is consisted with other report in that the altered A:G 
ratio was observed in diabetic rats [27]. Distinct metabolic renal alterations lead to a negative nitrogen 
balance, enhanced proteolysis and lowered protein synthesis in experimental diabetes [28]. The 
reversal of the changes by WSREt and WSLEt therapy may be proved that the insulin deficiency had 
been sufficiently corrected. Serum albumin and A:G ratio as well as total protein never deviated from 
the normal range throughout the treatment period in WSREt and WSLEt treated diabetic rats. W. 
somnifera has been reported to produce anabolic effects, enhancing the synthesis of certain modulator 
proteins in rat liver and increasing the bw in humans [29].  
Table 7. Effects of W. somnifera (L.) extracts on serum and tissue (liver, kidney and  
heart) proteins. 
Groups 
Serum 
total 
protein 
(g/dL) 
Albumin
(g/dL) 
Globulin
(g/dL) 
A:G 
ratio 
Liver 
protein 
Kidney 
protein 
Heart 
protein
Normal control 
7.13 ± 
1.76 b 
4.87 ± 
2.56 b 
2.44 ± 
0.18 a 
2.04 ± 
0.11 b 
8.24 ± 
2.38 b 
7.62 ± 
1.96 b 
6.31 ± 
1.76 b 
Diabetic control 
5.60 ± 
0.53 a 
3.21 ± 
0.31 a 
2.42 ± 
0.21 a 
1.34 ± 
0.09 a 
4.18 ± 
0.39 a 
5.26 ± 
0.50 a 
4.16 ± 
0.39 a 
Diabetic + WSREt 
6.93 ± 
0.56 b 
4.71 ± 
0.60 b 
2.18 ± 
0.12 a 
2.16 ± 
0.13 b 
7.91 ± 
0.56 b 
7.44 ± 
0.51 b 
6.18 ± 
0.80 b 
Diabetic + WSLEt 
7.08 ± 
0.64 b 
4.64 ± 
1.60 b 
2.35 ± 
0.22a 
1.98 ± 
0.10 b 
7.62 ± 
0.59 b 
6.81 ± 
0.70 b 
5.96 ± 
0.99 b 
Diabetic + glibenclamide
6.85 ± 
0.53 b 
4.60 ± 
1.17 b 
2.30 ± 
0.19a 
2.00 ± 
0.12 b 
8.01 ± 
0.84 b 
7.69 ± 
0.72 b 
5.88 ± 
0.66 b 
Values are expressed as mean ± SD of six samples from each group. Values with the same letter 
within columns are not significantly different using Duncan’s Multiple Range Test at 5% level  
(p ≤ 0.05). Both WSREt and WSLEt were treated at 200 mg/kg body weight. Tissue proteins are 
expressed as g/100g wet tissue. WSREt: W. somnifera root extract, WSLEt: W. somnifera leaf 
extract, A:G ratio: albumin/globulin. 
 
2.8. Effects of WSREt and WSLEt on liver glucose-6-phosphatase (G6P) and serum enzymes like 
aspartate transaminase (AST), alanine transaminase (ALT), acid phosphatase (ACP) and alkaline 
phosphatase (ALP) activities 
 
The effects of administering WSREt and WSLEt to diabetic rats on liver G6P and serum enzymes 
AST, ALT, ACP and ALP are given in Table 8. Alloxan administration increased liver function 
biomarkers such as ALP and ALT significantly in comparison with normal control rats [30]. The 
activities of liver G6P (220%) and serum enzymes like AST (181%), ALT (208%), ACP (156%) and 
ALP (124%) were significantly (p < 0.05) increased in the diabetic rats when compared to those of 
normal control rats. But the activities of liver G6P (55%) and serum AST (55%), ALT (60%), ACP 
(71%) and ALP (84%) were significantly (p < 0.05) decreased in diabetic rats treated with WSREt at 
the dose of 200 mg/kg bw when compared to those of diabetic rats. In addition, the administration of Int. J. Mol. Sci. 2009, 10                 
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WSLEt at the dose of 200 mg/kg bw also significantly reduced the liver G6P (52%) and AST (71%), 
ALT (55%), ACP (68%), and ALP (85%) activities in serum of diabetic rats. 
In the present study, the key gluconeogenic enzyme G6P activity was assayed in liver of diabetic 
rats because the liver is the main organ responsible for maintaining homeostasis of blood glucose. The 
activity of G6P is enhanced during diabetes [31]. The dearrangement in carbohydrate metabolism 
results in impaired glucose homeostasis leading to hyperglycaemia. WSREt and WSLEt replenished 
liver glycogen stores and suppressed the hepatic gluconeogenesis by decreasing activity of G6P. This 
result is accordance with the report of Bhavapriya et al. [32], in that the increased G6P activity is 
reversed by Aavirai kudineer (a herbal formulation) in diabetic rats. 
Table 8. Effects of W. somnifera (L.) extracts on liver G6P and serum enzymes AST, 
ALT, ACP and ALP.  
Groups G6P AST ALT  ACP  ALP 
Normal 
control 
11.68 ± 1.19 a  92.86 ± 6.64 a  69.38 ± 7.11 a  5.88 ± 1.78 a  17.93 ± 1.92 a 
Diabetic 
control 
25.72 ± 1.68 d  168.23 ± 7.12 c  144.19 ± 6.96 d  9.23 ± 2.00 b  22.19 ± 3.00 b 
Diabetic + 
WSREt  
14.22 ± 0.97 c  92.45 ± 6.53 a  86.27 ± 5.96 b  6.56 ± 2.22 a  18.62 ± 1.02 a 
Diabetic + 
WSLEt 
13.37 ± 0.90 bc  102.11 ± 6.89 b  79.05 ± 5.34 b  6.32 ± 0.71 a  18.92 ± 2.11 a 
Diabetic + 
glibenclamide 
12.18 ± 1.65 ab  96.68 ± 5.01 ab  76.44 ± 4.62 ab  5.92 ± 0.61 a  18.21 ± 2.74 a 
Values are expressed as mean ± SD of six samples from each group. Values with the same letter 
within columns are not significantly different using Duncan’s Multiple Range Test at 5% level  
(p ≤ 0.05). Both WSREt and WSLEt were treated at 200 mg/kg body weight. G6P is expressed as µ 
mole of pi liberated/min/mg protein and AST. ALT, ACP and ALP are expressed as IU/L. WSREt: 
W. somnifera (L.) root extract, WSLEt: W. somnifera (L.) leaf extract, G6P: glucose-6-phosphatase, 
AST: aspartate transaminase, ALT: alanine transaminase, ACP: acid phosphatase, ALP: alkaline 
phosphatase. 
 
In the present study the activities of AST, ALT, ACP and ALP in serum were altered in DM. In 
diabetic animals, the changes in the levels of AST, ALT, ACP and ALP are directly related to changes 
in metabolism in which the enzymes are involved. The increased activities of transaminases, which are 
active in the absence of insulin due to the availability of amino acids in the blood of DM [30,33] and 
are also responsible for the increased gluconeogenesis and ketogenesis. The restoration of AST and 
ALT to their respective normal level was observed in the WSREt and WSLEt treated groups. This is 
consistent with our previous report of the extracts of Chinese juniper berries [17]. AST and ALT levels 
also act as an indicator of liver function hence restoration of normal level of these enzymes indicates 
that the normal functioning of liver. Increased activities of serum ACP and ALP have been observed in 
alloxan diabetic rats [34]. Alloxan treated diabetes caused lipid peroxide mediated tissue damage in the 
pancrease, liver, kidney, and heart [34]. The increase in the levels of these enzymes in diabetes may be 
as a result of the leaking out from the tissues and then migrating into the blood stream [31]. Diabetes Int. J. Mol. Sci. 2009, 10                 
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and hyperlipidaemia also cause cell damage by altering the cell membrane architecture, which results 
in enhanced activities of ACP and ALP in diabetic rats. In WSREt, WSLEt and glibenclamide treated 
groups, the cell damage might be reverted and which may leads to the decreased activities of ACP and 
ALP. Therefore, the present study clearly indicates that WSREt and WSLEt possess hypoglycaemic 
and hypolipidaemic activities in alloxan induced DM rats.  
 
3. Experimental Section 
 
3.1. Chemicals 
 
Alloxan and quercetin dihydrate were purchased from Sigma Chemicals Co. (St Louis, Mo, USA) 
and Aldrich Chemicals Co. (Steineheim, Germany). Cholesterol, 1-amino-2-naphthol-4-sulphonic acid 
(ANSA), ammonium molybdate, sodium metaperiodate, citric acid monohydrate and acetyl acetone 
were purchased from Ranbaxy Chemicals (P) Ltd (Mumbai, India). Glycerol trioleate was purchased 
from Sisco Research Laboratories (P) Ltd (Mumbai, India). L-Aspartic acid, α-ketoglutaric acid, 2,4-
dinitrophenyl hydrazine, D-L-alanine and sodium β-glycerophosphate were obtained from Sd. Fine 
Chemicals, Mumbai, India. Sodium tungstate was obtained from Hi-Media Laboratories (New Delhi, 
India). All other chemicals and reagents, used in the present study, were of analytical reagent grade 
with high purity and were purchased from Loba Chemie (P) Ltd and E-Merck Chemicals (P) Ltd., 
(Mumbai, India) and Nice Chemicals (Kerala, India).  
 
3.2. Animals 
 
The experiments were carried out in forty two male healthy adult Albino Wistar strain rats (150 – 
180 g bw) procured from an authorized firm in Bangalore, India. They were housed in plastic cages 
with filter tops under controlled conditions of 12 h light/ 12 h dark cycle, 50% humidity and 28 ± 2 °C. 
They all received a standard pellet diet (Sri Saidurga Feed and Foods, Bangalore, India) and water ad 
libitum. The standard pellet diet contained 21% crude protein, 5% fat, 4% crude fiber, 8% ash, 1% 
calcium, 0.6% phosphorus, 2% vitamins and 55% nitrogen free extract (carbohydrates). The animals 
were maintained as per the principles and guidelines of the ethical committee for animal care of the 
Bharathidasan University (Tamilnadu, India) in accordance with the Indian National Law on Animal 
Care and Use (CPCSEA).  
 
3.3. Plant material 
 
Seeds of W. somnifera (L.) were procured from the Central Institute of Medicinal and Aromatic 
Plants (CIMAP), Lucknow, India and the plants were grown in the experimental garden. The plants 
were collected in the month of June 2006 and identified by Dr. A. Ganapathi, Professor and Botanist, 
Department of Biotechnology, Bharathidasan University, Tiruchirappalli, Tamilnadu, India. The plant 
parts like root and leaf were selected for the analysis of total flavonoids and antidiabetic activity.  
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3.4. Preparation of WSREt and WSLEt 
 
The parts (root and leaf) of the plant were collected from field grown plants in six months after 
planting. The collected parts of medicinal plant were brought into the laboratory, cleaned and dried in 
shade, and then ground to a fine powder. About 500 g of dry powder was extracted with ethanol (80%) 
at 70 °C by continuous hot percolation using a Soxhlet apparatus. The extraction was continued for  
24 h. The ethanolic extract was then filtered and kept in oven at 40 °C for 24 h to evaporate the ethanol 
from it. The concentrated extract was then dissolved in as little water as possible and washed three 
times with chloroform. The residual layer was extracted three times with ethyl acetate. All the extracts 
were finally pooled and concentrated using the rotary evaporator. A dark brown residue (extract) was 
obtained. The yield of extracts from root and leaf was about 76 and 72 g, respectively. The extracts 
were kept separately in air tight containers in a deep freezer until the time of use.  
 
3.5. Determination of total flavonoids in WSREt and WSLEt 
 
The content of flavonoids in the extracts of W. somnifera root and leaf was determined by 
spectrophotometrically according to the method of Quettier-Deleu et al. [35] using quercetin as a 
reference compound. One mL of plant extract in methanol (10 mg/mL) was mixed with 1 mL 
aluminium trichloride in ethanol (20 g/L) and diluted with ethanol to 25 mL. The absorption at 415 nm 
was read after 40 min at 20 °C. Blank sample was prepared from 1 mL plant extract and 1 drop acetic 
acid, and diluted to 25 mL. The absorption of quercetin solutions was measured under the same 
conditions. Standard quercetin solution was prepared from 0.05 g/L of quercetin. All determinations 
were carried out in triplicate. The amount of flavonoids was expressed as QE mg per 100 g of DW. 
 
3.6. Induction of diabetes mellitus in rats 
 
The rats were injected with alloxan monohydrate dissolved in sterile normal saline at a dose of  
150 mg/kg bw, intraperitoneally. The rats were then kept for the next 24 h on 5% glucose solution 
bottles in their cages to prevent hypoglycaemia [36]. After a fortnight, rats with moderate diabetes 
having glycosuria (indicated by Benedict’s test for urine) and hyperglycaemia with blood glucose 
range of 250 – 300 mg/dL were used for the experiment. Blood was collected from the eyes (venous 
pool) by sino-ocular puncture for the estimation of the blood glucose. 
 
3.7. Experimental design and treatment 
 
In the experiment a total number of 42 rats (36 diabetic induced rats and six normal rats) were used. 
Diabetes was induced in rats two weeks before starting the treatment. The rats were divided into seven 
groups as follows after the induction of alloxan diabetes and each group comprised of six rats. Group 
1: Normal control rats received only distilled water during the experimental period. Group 2: Diabetic 
control- freshly prepared alloxan in normal saline was administered in a single dose of 150 mg/kg bw 
through intraperitoneally to overnight fasted rats and the animals were allowed to develop diabetes for 
two weeks. Group 3: Diabetic rats were daily treated with WSREt at a dose of 100 mg/kg bw dissolved Int. J. Mol. Sci. 2009, 10                 
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in distilled water using an intragastric tube for eight weeks. Group 4: Diabetic rats were daily treated 
with WSREt at a dose of 200 mg/kg bw dissolved in distilled water using an intragastric tube for eight 
weeks. Group 5: Diabetic rats were daily treated with WSLEt at a dose of 100 mg/kg bw dissolved in 
distilled water using an intragastric tube for eight weeks. Group 6: Diabetic rats were daily treated 
with WSLEt at a dose of 200 mg/kg bw dissolved in distilled water using an intragastric tube for eight 
weeks. Group 7: Diabetic rats were orally treated with glibenclamide (0.6 mg/kg bw) dissolved in 
distilled water daily for eight weeks. 
 
3.8. Collection of samples 
 
The rats were carefully monitored every day and weighed every week. The sugar levels of urine and 
blood of all the rats were determined. After eight weeks of treatment the rats were sacrificed by 
cervical dislocation. Blood was collected and processed for the biochemical estimations. Tissues such 
as liver, kidney and heart were dissected out, washed in ice-cold saline patted dry and weighed 
accurately and used for lipid extraction by the method of Folch et al. [37] and further analysis.  
 
3.8.1. Determination of urine sugar, blood sugar, Hb, HbA1C and liver glycogen 
 
The urine sugar was detected by Benedict’s method [38]. Fasting blood glucose was estimated by 
the o-toluidene method [39]. Hb was estimated by Dacie and Lewis method [40] and HbA1C by 
Bannon’s method [41]. Liver glycogen was estimated by the method of Carroll et al. [42].  
 
3.8.2. Determination of serum lipid profile and tissues lipids like TC, TG and PL 
 
Serum lipids like TC and TG were determined by the method of Zlatkis et al. [43] and Foster and 
Dunn, [44] respectively. PL was estimated by the method of Zilversmit and Davis [45]. Lipoproteins 
were estimated by the method of Burstein et al. [46]. Tissues lipids like TC, TG and PL were also 
estimated by the above mentioned methods. 
 
3.8.3. Determination of serum and tissues protein  
 
Serum total proteins and tissues proteins from liver, kidney and heart were determined by the 
method of Lowry et al. [47]. Serum albumin was determined by the method of Reinhold [48] and then 
serum globulin was determined by the following formula: Globulin = total protein – albumin.  
 
3.8.4. Determination of assay of liver G6P and serum enzymes like AST, ALT, ACP and ALP  
 
Activity of G6P in the liver was assayed by the method of Koide and Oda [49]. The activities of 
serum AST and ALT were assayed by the method of Reitman and Frankel [50]. ACP and ALP were 
assayed by the method of King [51].  
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3.9. Statistical analysis 
 
Statistical evaluation was done using One Way Analysis of Variance (ANOVA) followed by 
Duncan's Multiple Range Test (DMRT) by using SPSS 11.09 for windows. The significance level was 
set at p < 0.05.  
 
4. Conclusions 
 
From the above results, it may be concluded that the W. somnifera root and leaf extracts possess 
antidiabetic and antihyperlipidaemic activities in alloxan-induced diabetic rats. W. somnifera root 
extract contained more flavonoids than leaf extract. Further, phytochemical characterization of W. 
somnifera is required to identify the specific compound(s) involved in the observed hypoglycaemic 
and hypolipidaemic activities.  
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